ADPT Key Statistics, Chart & Performance
The current stock price of ADPT is 14.75 USD. In the past month the price decreased by -5.21%. In the past year, price increased by 135.25%.
ADPT Latest News, Press Relases and Analysis
ADPT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.57 | 215.20B | ||
| DHR | DANAHER CORP | 29.35 | 159.81B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 186.35 | 56.63B | ||
| A | AGILENT TECHNOLOGIES INC | 26.07 | 41.25B | ||
| IQV | IQVIA HOLDINGS INC | 19.42 | 38.46B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 33.82 | 28.91B | ||
| WAT | WATERS CORP | 31.09 | 23.50B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 39.64 | 20.16B | ||
| ILMN | ILLUMINA INC | 29.58 | 19.71B | ||
| MEDP | MEDPACE HOLDINGS INC | 38.33 | 15.44B | ||
| TEM | TEMPUS AI INC | N/A | 13.64B | ||
| RVTY | REVVITY INC | 21.04 | 11.43B |
Related stock screener links
About ADPT
Company Profile
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 619 full-time employees. The company went IPO on 2019-06-27. The firm is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. The company applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
Company Info
ADAPTIVE BIOTECHNOLOGIES
1165 Eastlake Ave E
Seattle WASHINGTON 98102 US
CEO: Chad Robins
Employees: 619
Phone: 12066590067
ADAPTIVE BIOTECHNOLOGIES / ADPT FAQ
Can you describe the business of ADAPTIVE BIOTECHNOLOGIES?
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 619 full-time employees. The company went IPO on 2019-06-27. The firm is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. The company applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
What is the stock price of ADAPTIVE BIOTECHNOLOGIES today?
The current stock price of ADPT is 14.75 USD. The price decreased by -15.52% in the last trading session.
Does ADPT stock pay dividends?
ADPT does not pay a dividend.
What is the ChartMill technical and fundamental rating of ADPT stock?
ADPT has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is ADAPTIVE BIOTECHNOLOGIES (ADPT) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ADPT.
What is the employee count for ADPT stock?
ADAPTIVE BIOTECHNOLOGIES (ADPT) currently has 619 employees.
What is the market capitalization of ADPT stock?
ADAPTIVE BIOTECHNOLOGIES (ADPT) has a market capitalization of 2.25B USD. This makes ADPT a Mid Cap stock.
ADPT Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ADPT. When comparing the yearly performance of all stocks, ADPT is one of the better performing stocks in the market, outperforming 95.59% of all stocks.
ADPT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ADPT. Both the profitability and financial health of ADPT have multiple concerns.
ADPT Financial Highlights
Over the last trailing twelve months ADPT reported a non-GAAP Earnings per Share(EPS) of -0.54. The EPS increased by 53.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.29% | ||
| ROE | -39.09% | ||
| Debt/Equity | 0.63 |
ADPT Forecast & Estimates
14 analysts have analysed ADPT and the average price target is 20.69 USD. This implies a price increase of 40.28% is expected in the next year compared to the current price of 14.75.
For the next year, analysts expect an EPS growth of 54.26% and a revenue growth 48.93% for ADPT